Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Sep 3;2015(9):CD005399.
doi: 10.1002/14651858.CD005399.pub3.

Pharmacological interventions for epilepsy in people with intellectual disabilities

Cerian F Jackson  1 , Selina M Makin, Anthony G Marson, Michael Kerr
Affiliations
Meta-Analysis

Pharmacological interventions for epilepsy in people with intellectual disabilities

Cerian F Jackson et al. Cochrane Database Syst Rev. .

Abstract

Background: The prevalence of epilepsy among people with intellectual disabilities is much higher than in the general population. Seizures in this population are often complex and refractory to treatment and antiepileptic medication may have a profound effect upon behaviour (Kerr 1997).This is an updated version of a Cochrane Review first published in Issue 3, 2007.

Objectives: To assess the data available from randomised controlled trials (RCTs) of the efficacy of antiepileptic drug (AED) interventions in people with epilepsy and intellectual disabilities.

Search methods: For the latest update of this review, we searched the Cochrane Epilepsy Group Specialised Register (2 September 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO) (2 September 2014), MEDLINE (Ovid, 1946 to 3 September 2014) and PsycINFO (EBSCOhost, 1887 to 3 September 2014).

Selection criteria: Randomised and quasi-randomised controlled trials (RCTs) of pharmacological interventions for people with epilepsy and a learning disability.

Data collection and analysis: Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional information. We assessed epilepsy/seizure, behavioural and cognitive outcomes, as well as quality of life and adverse effects.

Main results: We included 14 RCTs (1116 participants) in the present review. Data were heterogenous and a descriptive analysis is presented. In the majority of cases where antiepileptic drugs (AEDs) were trialled in this population, we found moderate reductions in seizure frequency in that there was a significantly higher rate of responders (reduction of 50% or more) in the treatment group compared with the placebo group, with some studies reporting a higher incidence of seizure freedom in the treatment group. In general, AEDs that are proven to be effective in the general epilepsy population are also effective for refractory epilepsy in people with intellectual disability. It is not possible to comment on the relative efficacy of medications, making clinical decisions difficult.In trial settings patients continued on treatment in the majority of cases. Placebo groups often experienced fewer adverse events. Where adverse events were experienced they appeared similar to those in the general population. The methods by which adverse events were recorded and reported appeared to be inconsistent, resulting in very large variation between studies. This is problematic as clinically relevant interpretation of these findings is limited.The quality of evidence provided in the present review is low to moderate. Additionally the majority of studies lacked or used non-reliable measures of behavioural exacerbation. However, where measured, little obvious impact on behaviour was seen in terms of behaviour disorder.

Authors' conclusions: This review broadly supports the use of AEDs to reduce seizure frequency in people with refractory epilepsy and intellectual disability. The evidence suggests that adverse events are similar to those in the general population and that behavioural adverse events leading to discontinuation are rare; however, other adverse effects are under-researched.

PubMed Disclaimer

Conflict of interest statement

MK was an author on two of the papers reviewed in this article.

CFJ;SMM;AGM have no known declarations of interest.

Figures

1
1
Study flow diagram.
2
2
'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
1.1
1.1. Analysis
Comparison 1 AED vs placebo, Outcome 1 Responder rate (≥ 50% reduction in overall seizure frequency).
1.2
1.2. Analysis
Comparison 1 AED vs placebo, Outcome 2 Responder rate (≥ 50% reduction in rate of drop seizures).
1.3
1.3. Analysis
Comparison 1 AED vs placebo, Outcome 3 Seizure freedom.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Battaglia 1991 {published data only}
    1. Battaglia A, Ferrari AR, Guerrini R. Double‐blind placebo‐controlled trial of flunarizine as add‐on therapy in refractory childhood epilepsy. Brain & Development 1991;13(4):217‐22. - PubMed
Crawford 2001 {published data only}
    1. Crawford P, Brown S, Kerr M, Parke Davis Clinical Trials Group. A randomized open‐label study of gabapentin and lamotrigine in adults with learning disability and resistant epilepsy. Seizure 2001;10(2):107‐15. - PubMed
Crumrine 1989 {published data only}
    1. Crumrine P, Dreifuss FE, Corwin H, et al. Double‐blind, placebo‐controlled evaluation of cinromide in patients with the Lennox‐Gastaut Syndrome. Epilepsia 1989;30(4):422‐9. - PubMed
Eriksson 1998 {published data only}
    1. Eriksson AS, Nergardh A, Hoppu K. The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double‐blind, crossover study. Epilepsia 1998;39(5):495‐501. - PubMed
Gigli 1988 {published data only}
    1. Gigli GL, Mazza S, Valente RM, Colognola RM, Musumeci R. Ineffectiveness of add‐on treatment with flunarizine in patients with epilepsy and mental retardation [Inefficacia dell'aggiunta di flunarizina al trattamento di pazienti con epilessia e ritardo mental: risultati di uno studio cross‐over in doppio cieco]. Il Bolletino della Lega Italiana contro l'Epilessia 1988;62(63):417‐8.
Glauser 2008 {published data only}
    1. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox‐Gastaut syndrome. Neurology 2008;70(21):1950‐8. - PubMed
Kaski 1991 {published data only}
    1. Kaski M, Heinonen E, Sivenius J, Tuominen J, Anttila M. Treatment of epilepsy in mentally retarded patients with a slow‐release carbamazepine preparation. Journal of Mental Deficiency Research 1991;35(3):231‐9. - PubMed
Kerr 2005 {published data only}
    1. Kerr MP, Baker GA, Brodie MJ. A randomized, double‐blind, placebo‐controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsy & Behavior 2005;7(3):472‐80. - PubMed
Motte 1997 {published data only}
    1. Billard C, Motte J, Arvidsson D, Trevathan E, Talladai M, Campos J, et al. Double‐blind, placebo‐controlled evaluation of the safety and efficacy of lamotrigine (Lamictal) for the treatment of patients with a clinical diagnosis of Lennox‐Gastaut syndrome. Epilepsia 1996;37(Suppl 4):92.
    1. Motte J, Trevathan E, Arvidsson JFV, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox‐Gastaut syndrome. New England Journal of Medicine 1997;337(25):1807‐12. - PubMed
    1. Mullens L, Gallagher J, Manasco P. Improved neurological function accompanies effective control of the Lennox‐Gastaut syndrome with Lamictal: results of a multinational, placebo‐controlled trial. Epilepsia 1996;37(Suppl 5):163.
Ng 2011 {published data only}
    1. Ng YT, Conry JA, Drummond R, Stolle J, Weinberg MA. Randomized, phase III study of clobazam in Lennox‐Gastaut syndrome. Neurology 2011;77(15):1473‐81. - PubMed
Ritter 1993 {published data only}
    1. Jensen PK. Felbamate in the treatment of Lennox‐Gastaut syndrome. Epilepsia 1994;35(Suppl 5):S54‐7. - PubMed
    1. Ritter F, Dreifuss FE, Sackellares JC, Shields D, French J, Dodson WE. A double‐blind trial of felbamate in Lennox‐Gastaut syndrome. Epilepsia 1991;32(Suppl 3):13.
    1. Ritter FJ, Leppik IE, Dreifuss FE, et al. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox‐Gastaut syndrome). New England Journal of Medicine 1993;328(1):29‐33. - PubMed
    1. Vigevano F, Cilio MR, Antonini L. Clinical experience with felbamate in paediatric age [Esperienze con Felbamato in eta pediatrica]. Lega Italiana conto l'Epilessia 1994;86‐7:63‐6.
Sachdeo 1999 {published data only}
    1. Glauser TA, Sachdeo RC, Ritter FJ, Reife R, Lim P. A double‐blind trial of topiramate in Lennox‐Gastaut syndrome (LGS). Epilepsia 1997;38(Suppl 3):131. - PubMed
    1. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double‐blind, randomized trial of topiramate in Lennox‐Gastaut syndrome. Topiramate YL Study Group. Neurology 1999;52(9):1882‐7. - PubMed
Siegel 1999 {published data only}
    1. Oletsky H, Kelley K, Stertz B, Reeves‐Tyer P, Flamini R, Malow B, et al. The efficacy of felbamate as add‐on therapy to valproic acid in the Lennox‐Gastaut syndrome (LGS). Epilepsia 1996;37(Suppl 5):155. - PubMed
    1. Siegel H, Kelley K, Stertz B, Reeves‐Tyer P, Flamini R, Malow B, et al. The efficacy of felbamate as add‐on therapy to valproic acid in the Lennox‐Gastaut syndrome. Epilepsy Research 1999;34(2‐3):91‐7. - PubMed
Yamatogi 1997 {published data only}
    1. Yamatogi Y, Ohtahara S, Shigematsu H, et al. Single blind comparative study of clobazam (NH‐15) with clonazepam in intractable childhood epilepsies. Journal of the Japan Epilepsy Society 1997;15(2):110‐21.

References to studies excluded from this review

Bielmann 1978 {published data only}
    1. Bielmann P, Levac T, Gagnon MA. Clonazepam: its efficacy in association with phenytoin and phenobarbital in mental patients with generalized major motor seizures. International Journal of Clinical Pharmacology and Biopharmacy 1978;16(6):268‐73. - PubMed
Bjornaes 2013 {published data only}
    1. Bjornaes H, Bakke KA, Larsson PG, Heminghyt E, Rytter E, Brager‐Larsen LM. Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behaviour before and after treatment with levetiracetam. Epilepsy & Behavior 2013;27(1):40‐8. - PubMed
Conry 2014 {published data only}
    1. Conry JA, Ng T‐T, Kernitsky L, Mitchell WG, Veidemanis R, Drummond R, et al. Stable dosages of clobazam for Lennox‐Gastaut syndrome are associated with sustained drop‐seizure and total seizure improvements over 3 years. Epilepsia 2014;55(4):558‐67. - PMC - PubMed
Donati 2006 {published data only}
    1. Donati F, Gobbi G, Campistol J, Rapatz G, Daehler M, Sturm Y, et al. Effects of oxcarbazepine on cognitive function in children and adolescents with partial seizures. Neurology 2006;67(4):679‐82. - PubMed
Espe‐Lillo 1992 {published data only}
    1. Espe‐Lillo J, Ritter FJ. Long‐term follow‐up of felbamate treatment in children with Lennox‐Gastaut Syndrome. Epilepsia 1992;33(Suppl 3):118.
Gidal 2013 {published data only}
    1. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration‐effect relationships with perampanel in patients with pharmacoresistant partial‐onset seizures. Epilepsia 2013;54(8):1490‐7. - PubMed
Hagebeuk 2011 {published data only}
    1. Hagebeuk EEO, Koelman J, Duran M, Abeling NG, Vyth A, Poll‐The BT. Clinical and electroencephalographic effects of folinic acid treatment in Rett syndrome patients. Journal of Child Neurology 2011;26(6):718‐23. - PubMed
Hellings 2009 {published data only}
    1. Hellings JA, Barth FX, Logan M, Cook‐Wiens G, Osorio I, Reed RC. Overnight versus progressive conversion of multiple daily‐dose divalproex to once‐daily divalproex extended release: which strategy is better tolerated by adults with intellectual disabilities?. Journal of Clinical Psychopharmacology 2009;29(5):492‐5. - PubMed
Hodoba 2013 {published data only}
    1. Hodoba S, Santic AM, Schmidt D. Adjunctive Madopar for ultrarefractory epilepsy? Preliminary observations. Epilepsy & Behavior 2013;28(2):201‐2. - PubMed
Luna 1989 {published data only}
    1. Luna D, Dulac O, Pajot N, Beaumont D. Vigabatrin in the treatment of childhood epilepsies: a single‐blind placebo‐controlled study. Epilepsia 1989;30(4):430‐7. - PubMed
Santos 2013 {published data only}
    1. Santos K, Palmini A, Radziuk AL, Robert R, Bastos F, Booij L, et al. The impact of methylphenidate on seizure frequency and severity in children with attention‐deficit‐hyperactivity disorder and difficult‐to‐treat epilepsies. Developmental Medicine & Child Neurology 2013;55(7):654‐60. - PubMed
Schlumberger 1994 {published data only}
    1. Schlumberger E, Dulac O. A simple, effective and well‐tolerated treatment regime for West syndrome. Developmental Medicine and Child Neurology 1994;36(10):863‐72. - PubMed
Smith 1968 {published data only}
    1. Smith WL, Philippus MJ, Guard HL. Psychometric study of children with learning problems and 14‐6 positive spike EEG patterns, treated with ethosuximide (Zarontin) and placebo. Archives of Disease in Childhood 1968;43(231):616‐9. - PMC - PubMed
Tolbert 2014 {published data only}
    1. Tolbert D, Harris SI, Bekersky I, Lee D, Isojarvi J. Withdrawal‐related adverse events from clinical trials of clobazam in Lennox‐Gastaut syndrome. Epilepsy & Behavior 2014;37:11‐5. - PubMed
Turner 1970 {published data only}
    1. Turner M, Cordero Funes JR, Aspinwall R, Cantlon B, Fejerman N, Loñ JC. Clinico‐electroencephalographic evaluation of a new benzodiazepine (Ro 05‐4023) by oral administration in epileptic patients by double blind technique. Acta Neurologica Latinoamericana 1970;16(1):158‐69. - PubMed

References to ongoing studies

Bjurulf 2008 {published data only}
    1. Bjurulf B. Comparing ketogenic diet with the most appropriate antiepileptic drug ‐ a randomized study of children with mental retardation and drug resistant epilepsy. www.clinicaltrials.gov/ct/show/NCT00552526 (accessed 7 August 2008).

Additional references

Al‐Bachari 2013
    1. Al‐Bachari S, Pulman J, Hutton JL, Marson AG. Gabapentin add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD001415.pub2] - DOI - PubMed
Beran 1998
    1. Beran RG, Gibson RJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998;39(3):280‐2. - PubMed
Besag 2001
    1. Besag FM. Behavioural effects of the new anticonvulsants. Drug Safety 2001;24(7):513‐36. - PubMed
Bouras 1992
    1. Bouras N, Drummond C. Behaviour and psychiatric disorders of people with mental handicaps living in the community. Journal of Intellectual Disability Research 1992;36(4):349‐57. - PubMed
Bowley 2000
    1. Bowley C, Kerr M. Epilepsy and intellectual disability. Journal of Intellectual Disability Research 2000;44(5):529‐43. - PubMed
Dam 1990
    1. Dam M. Vigabatrin and behaviour disturbances (Letter). Lancet 1990;335:8689. - PubMed
Deb 1997
    1. Deb S. Mental disorder in adults with mental retardation and epilepsy. Comprehensive Psychiatry 1997;38(3):179‐84. - PubMed
Deb 1999
    1. Deb S, Joyce J. Characteristics of epilepsy in a population based cohort of adults with learning disability. Irish Journal of Psychological Medicine 1999;16(1):5‐9.
Dulac 1991
    1. Dulac O, Chiron C, Luna D, Cusmai R, Pajot N, Beaumont D, et al. Vigabatrin in childhood epilepsy. Journal of Child Neurology 1991;6(Suppl 2):S30‐7. - PubMed
Eaton 1982
    1. Eaton LF, Menolascino FJ. Psychiatric disorders in the mentally retarded: types, problems, and challenges. American Journal of Psychiatry 1982;139(10):1297‐303. - PubMed
Espie 1989
    1. Espie CA, Pashley AS, Bonham KG, Sourindhrin I, O'Donovan M. The mentally handicapped person with epilepsy: a comparative study investigating psychosocial functioning. Journal of Mental Deficiency Research 1989;33(2):123‐35. - PubMed
Espie 1990
    1. Espie CA, Gillies JB, Montgomery JM. Antiepileptic polypharmacy, psychosocial behaviour and locus of control orientation among mentally handicapped adults living in the community. Journal of Mental Deficiency Research 1990;34(4):351‐60. - PubMed
Ettinger 1998
    1. Ettinger AB, Weisbrot DM, Saracco J, Dhoon A, Kanner A, Devinsky O. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998;39(8):874‐7. - PubMed
Forsgren 1990
    1. Forsgren L, Edvinsson SO, Blomquist HK, Heijbel J, Sidenvall R. Epilepsy in a population of mentally retarded children and adults. Epilepsy Research 1990;6(3):234‐48. - PubMed
Gay 1995
    1. Gay PE, Mecham GF, Coskey JS, Sadler T, Thompson JA. Behavioural effects of felbamate in childhood epileptic encephalopathy (Lennox‐Gastaut syndrome). Psychological Reports 1995;77(3 Pt 2):1208‐10. - PubMed
Gillies 1989
    1. Gillies JB, Espie CA, Montgomery JM. The social and behavioural functioning of people with mental handicaps attending adult training centres: a comparison with those with and without epilepsy. Mental Handicap Research 1989;2:129‐36.
Goulden 1991
    1. Goulden K, Shinnar S, Koller H, Katz M, Richardson S. Epilepsy in children with mental retardation: a cohort study. Epilepsia 1991;34:690‐7. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoare 1984
    1. Hoare P. The development of psychiatric disorder among school children with epilepsy. Developmental Medicine and Child Neurology 1984;26(1):3‐13. - PubMed
ILAE 1981
    1. Commission on Classification and Terminology of the ILAE: proposal for revised clinical and EEG classification of epileptic seizures. Epilepsia 1981;22:489‐501. - PubMed
ILAE 1989
    1. Commission on Classification and Terminology of the ILAE: proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30:389‐99. - PubMed
Kerr 1997
    1. Kerr MP, Espie CA. Learning disability and epilepsy. Seizure 1997;6(5):331‐6. - PubMed
Khurana 1996
    1. Khurana DS, Riviello J, Helmers S, Holmes G, Anderson J, Mikati MA. Efficacy of gabapentin therapy in children with refractory partial seizures. Journal of Pediatrics 1996;128(6):829‐33. - PubMed
Kirkham 2010
    1. Kirkham JJ, Swan KM, Altman DG, Gamble C, Dodd S, Smyth R, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010;340:365. - PubMed
Lee 1996
    1. Lee DO, Steingard RJ, Cesena M, Helmers SL, Riviello JJ, Mikati MA. Behavioral side effects of gabapentin in children. Epilepsia 1996;37(1):87‐90. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Mansell 1993
    1. Mansell JL. Services for People with Learning Disabilities and Challenging Behaviour or Mental Health Needs. London: HMSO, 1993.
Mariani 1993
    1. Mariani E, Ferini‐Strambi L, Sala M, Erminio C, Smirne S. Epilepsy in institutionalized patients with encephalopathy: clinical aspects and nosological considerations. American Journal of Mental Retardation 1993;98:27‐33. - PubMed
Michael 2008
    1. Michael B, Marson AG. Clobazam as an add‐on in the management of refractory epilepsy. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD004154.pub4] - DOI - PubMed
Mikati 1998
    1. Mikati MA, Choueri R, Khurana DS, Riviello J, Helmers S, Holmes G. Gabapentin in the treatment of refractory partial epilepsy in children with intellectual disability. Journal of Intellectual Disability Research 1998;1:57‐62. - PubMed
Morgan 2003
    1. Morgan CL, Baxter H, Kerr MP. Prevalence of epilepsy and associated health service utilization and mortality among patients with intellectual disability. American Journal of Mental Retardation 2003;108(5):293‐300. - PubMed
Mullens 1996
    1. Mullens L, Gallagher J, Manasco P. Improved neurological function accompanies effective control of the Lennox‐Gastaut syndrome with Lamictal: results of a multinational, placebo‐controlled trial. Epilepsia 1996;37(Suppl 5):163.
Pulman 2014
    1. Pulman J, Jette N, Dykeman J, Hemming K, Hutton JL, Marson AG. Topiramate add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews 2014, Issue 2. [DOI: 10.1002/14651858.CD001417.pub3] - DOI - PubMed
Ramaratnam 2001
    1. Ramaratnam S, Marson AG, Baker G. Lamotrigine add‐on for drug‐resistant partial epilepsy. Cochrane Database of Systematic Reviews 2001, Issue 3. [DOI: 10.1002/14651858.CD001909] - DOI - PubMed
Rugg‐Gunn 2012
    1. Rugg‐Gunn FJ, Sander JW. Management of chronic epilepsy. BMJ (Clinical Research Ed.) 2012;345:4576. - PubMed
Shepherd 1989
    1. Shepherd C, Hosking G. Epilepsy in school children with intellectual impairments in Sheffield: the size and nature of the problem and its implications in service provision. Journal of Mental Deficiency Research 1989;33:511‐4. - PubMed
Shi 2014
    1. Shi LL, Dong J, Ni H, Geng J, Wu T. Felbamate as an add‐on therapy for refractory epilepsy. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD008295.pub3] - DOI - PubMed
Stafstrom 1993
    1. Stafstrom C. Epilepsy in Down's syndrome: clinical aspects and possible mechanisms. American Journal of Mental Retardation 1993;98:12‐26. - PubMed
Turky 2011
    1. Turky A, Felce D, Jones G, Kerr M. A prospective case control study of psychiatric disorders in adults with epilepsy and intellectual disability. Epilepsia 2011;52:1223‐30. - PubMed
Wallace 1996
    1. Wallace SJ. A comparative review of the adverse effects of anticonvulsants in children with epilepsy. Drug Safety 1996;15(6):378‐93. - PubMed
Webb 1991
    1. Webb D, Fryer A, Osborne J. On the incidence of fits and mental retardation in tuberous sclerosis. Journal of Medical Genetics 1991;6:395‐7. - PMC - PubMed
Wolf 1995
    1. Wolf SM, Shinnar S, Kang H, Gil KB, Moshe SL. Gabapentin toxicity in children manifesting as behavioural changes. Epilepsia 1995;36(12):1203‐5. - PubMed

References to other published versions of this review

Beavis 2007a
    1. Beavis J, Kerr M, Marson AG. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD005399.pub2] - DOI - PubMed
Beavis 2007b
    1. Beavis J, Kerr M, Marson AG, Dojcinov I. Pharmacological interventions for epilepsy in people with intellectual disabilities. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD005399.pub2] - DOI - PubMed

Publication types

MeSH terms

Substances